Sequencing of individual clones from a newly established cDNA library from the chemoresistant Hodgkin's lymphoma cell line L-1236 led to the isolation of a cDNA clone corresponding to a short sequence from chromosome 1. Reverse transcriptase-polymerase chain reaction indicated high expression of this sequence in Hodgkin's lymphoma derived cell lines but not in normal blood cells. Further characterization of this sequence and the surrounding genomic DNA revealed that this sequence is part of a human endogenous retrovirus locus. The sequence of this endogenous retrovirus is interrupted by a pseudogene of the dual specificity phosphatase 5 (DUSP5). Reverse transcriptase-polymerase chain reaction revealed high expression of this pseudogene (DUSP5P1) in HL cell lines but not in normal blood cells or Epstein-Barr virus-immortalized B cells. Cells from other tumor types (Burkitt's lymphoma, leukemia, neuroblastoma, Ewing sarcoma) also showed a higher DUSP5P1/DUSP5 ratio than normal cells. Furthermore, we observed that higher expression of DUSP5 in relation to DUSP5P1 correlated with the expression of the pro-apoptotic factor B cell leukemia/lymphoma 2-like 11 (BCL2L11) in peripheral blood cells and HL cells. Knock-down of DUSP5 in HL cells resulted in down-regulation of BCL2L11. Thus, the DUSP5/DUSP5P1 system could be responsible for regulation of BCL2L11 leading to inhibition of apoptosis in these tumor cells.
References
[1]
Mauz-K？rholz C, Hasenclever D, D？rffel W, Ruschke K, Pelz T, et al. (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 28: 3680–3686. doi: 10.1200/jco.2009.26.9381
[2]
Lin HM, Teitell MA (2005) Second malignancy after treatment of pediatric Hodgkin disease. J Pediatr Hematol Oncol 27: 28–36. doi: 10.1097/01.mph.0000150740.80690.d4
[3]
Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van't Veer MB, Baaijens MH, et al. (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109: 1878–1886. doi: 10.1182/blood-2006-07-034405
[4]
Sieniawski M, Reineke T, Josting A, Nogova L, Behringer K, et al. (2008) Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials. Ann Oncol 19: 1795–1801. doi: 10.1093/annonc/mdn376
[5]
McCullough L, Ng A, Najita J, Janov A, Henderson T, et al. (2010) Breastfeeding in survivors of Hodgkin lymphoma treated with chest radiotherapy. Cancer 116: 4866–4871. doi: 10.1002/cncr.25442
[6]
Haase R, Vilser C, Mauz-K？rholz C, Hasenclever D, Kluge R, et al. (2012) Evaluation of the prognostic meaning of C-reactive protein (CRP) in children and adolescents with classical Hodgkin's lymphoma (HL). Klin Padiatr 224: 377–381. doi: 10.1055/s-0032-1323824
[7]
Staege MS, Banning-Eichenseer U, Weissflog G, Volkmer I, Burdach S, et al. (2008) Gene expression profiles of Hodgkin's lymphoma cell lines with different sensitivity to cytotoxic drugs. Exp Hematol 36: 886–896. doi: 10.1016/j.exphem.2008.02.014
[8]
Staege MS, Hattenhorst UE, Neumann UE, Hutter C, Foja S, Burdach S (2003) DNA-microarrays as tools for the identification of tumor specific gene expression profiles: applications in tumor biology, diagnosis and therapy. Klin Padiatr 15: 135–139. doi: 10.1055/s-2003-39371
[9]
Seed B, Aruffo A (1987) Molecular cloning of the CD2 antigen, the T-cell erythrocyte receptor, by a rapid immunoselection procedure. Proc Natl Acad Sci U S A 84: 3365–3369. doi: 10.1073/pnas.84.10.3365
Ruprecht K, Mayer J, Sauter M, Roemer K, Mueller-Lantzsch N (2008) Endogenous retroviruses and cancer. Cell Mol Life Sci 65: 3366–3382. doi: 10.1007/s00018-008-8496-1
[12]
Balada E, Vilardell-Tarrés M, Ordi-Ros J (2010) Implication of human endogenous retroviruses in the development of autoimmune diseases. Int Rev Immunol 29: 351–370. doi: 10.3109/08830185.2010.485333
[13]
Christensen T (2010) HERVs in neuropathogenesis. J Neuroimmune Pharmacol 5: 326–335. doi: 10.1007/s11481-010-9214-y
[14]
Lamprecht B, Walter K, Kreher S, Kumar R, Hummel M, et al. (2010) Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma. Nat Med 16: 571–579. doi: 10.1038/nm.2129
[15]
Caunt CJ, Keyse SM (2013) Dual-specificity MAP kinase phosphatases (MKPs): shaping the outcome of MAP kinase signalling. FEBS J 280: 489–504. doi: 10.1111/j.1742-4658.2012.08716.x
[16]
Wolf J, Kapp U, Bohlen H, Kornacker M, Schoch C, et al. (1996) Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells. Blood 87: 3418–3428.
[17]
Diehl V, Kirchner HH, Schaadt M, Fonatsch C, Stein H, et al. (1981) Hodgkin's disease: establishment and characterization of four in vitro cell lines. J Cancer Res Clin Onco 101: 111–124. doi: 10.1007/bf00405072
[18]
Drexler HG, Gaedicke G, Lok MS, Diehl V, Minowada J (1986) Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles. Leuk Res 10: 487–500. doi: 10.1016/0145-2126(86)90084-6
[19]
Kamesaki H, Fukuhara S, Tatsumi E, Uchino H, Yamabe H, et al. (1986) Cytochemical, immunologic, chromosomal, and molecular genetic analysis of a novel cell line derived from Hodgkin's disease. Blood 68: 285–292.
[20]
Hoennscheidt C, Max D, Richter N, Staege MS (2009) Expression of CD4 on Epstein-Barr virus-immortalized B cells. Scand J Immunol 70: 216–225. doi: 10.1111/j.1365-3083.2009.02286.x
[21]
Foell JL, Volkmer I, Giersberg C, Kornhuber M, Horneff G, Staege MS (2008) Loss of detectability of Charcot-Leyden crystal protein transcripts in blood cells after treatment with dimethyl sulfoxide. J Immunol Methods 339: 99–103. doi: 10.1016/j.jim.2008.08.006
[22]
Neumann I, Foell JL, Bremer M, Volkmer I, Korholz D, et al. (2010) Retinoic acid enhances sensitivity of neuroblastoma cells for imatinib mesylate. Pediatr Blood Cancer 55: 464–470. doi: 10.1002/pbc.22603
[23]
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408. doi: 10.1006/meth.2001.1262
[24]
Altschul SF, Madden TL, Sch？ffer AA, Zhang J, Zhang Z, et al. (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25: 3389–3402. doi: 10.1093/nar/25.17.3389
[25]
Villesen P, Aagaard L, Wiuf C, Pedersen FS (2004) Identification of endogenous retroviral reading frames in the human genome. Retrovirology 1: 32. doi: 10.1186/1742-4690-1-32
[26]
Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673–4680. doi: 10.1093/nar/22.22.4673
[27]
Reese M (2001) Application of a time-delay neural network to promoter annotation in the Drosophila melanogaster genome. Comput Chem 26: 51–56. doi: 10.1016/s0097-8485(01)00099-7
[28]
Arnold K, Bordoli L, Kopp J, Schwede T (2006) The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics 22: 195–201. doi: 10.1093/bioinformatics/bti770
[29]
Farooq A, Chaturvedi G, Mujtaba S, Plotnikova O, Zeng L, et al. (2001) Solution structure of ERK2 binding domain of MAPK phosphatase MKP-3: structural insights into MKP-3 activation by ERK2. Mol Cell 7: 387–399. doi: 10.1016/s1097-2765(01)00186-1
[30]
Küppers R (2009) Molecular biology of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009: 491–496. doi: 10.1182/asheducation-2009.1.491
[31]
Carbone A, Gloghini A, Dotti G (2008) EBV-associated lymphoproliferative disorders: classification and treatment. Oncologist 13: 577–585. doi: 10.1634/theoncologist.2008-0036
[32]
Ambinder RF (2007) Epstein-Barr virus and Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007: 204–209. doi: 10.1182/asheducation-2007.1.204
[33]
Benharroch D, Shemer-Avni Y, Myint YY, Levy A, Mejirovsky E, et al. (2004) Measles virus: evidence of an association with Hodgkin's disease. Br J Cancer 91: 572–579.
[34]
Huang G, Yan Q, Wang Z, Chen X, Zhang X, et al. (2002) Human cytomegalovirus in neoplastic cells of Epstein-Barr virus negative Hodgkin's disease. Int J Oncol 21: 31–36. doi: 10.3892/ijo.21.1.31
[35]
Figueiredo CP, Franz-Vasconcelos HC, Giunta Gd, Mazzuco TL, Caon T, et al. (2007) Detection of Torque teno virus in Epstein-Barr virus positive and negative lymph nodes of patients with Hodgkin lymphoma. Leuk Lymphoma 48: 731–735. doi: 10.1080/10428190701203954
[36]
Lacroix A, Collot-Teixeira S, Mardivirin L, Jaccard A, Petit B, et al. (2010) Involvement of human herpesvirus-6 variant B in classic Hodgkin's lymphoma via DR7 oncoprotein. Clin Cancer Res 16: 4711–4721. doi: 10.1158/1078-0432.ccr-10-0470
[37]
Chezzi C, Dettori G, Manzari V, Aglianò AM, Sanna A (1976) Simultaneous detection of reverse transcriptase and high molecular weight RNA in tissue of patients with Hodgkin's disease and patients with leukemia. Proc Natl Acad Sci U S A 73: 4649–4652. doi: 10.1073/pnas.73.12.4649
[38]
Hsiao FC, Tai AK, Deglon A, Sutkowski N, Longnecker R, Huber BT (2009) EBV LMP-2A employs a novel mechanism to transactivate the HERV-K18 superantigen through its ITAM. Virology 385: 261–266. doi: 10.1016/j.virol.2008.11.025
[39]
Tai AK, Luka J, Ablashi D, Huber BT (2009) HHV-6A infection induces expression of HERV-K18-encoded superantigen. J Clin Virol 46: 47–48. doi: 10.1016/j.jcv.2009.05.019
[40]
Gergely P Jr, Pullmann R, Stancato C, Otvos L Jr, Koncz A, et al. (2005) Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus. Clin Immunol 116: 124–134. doi: 10.1016/j.clim.2005.04.002
[41]
Habek M, Brinar VV, Hajnsek S (2008) The association of multiple sclerosis and Hodgkin's disease: the role of Epstein-Barr virus infection. Mult Scler 14: 284–287. doi: 10.1177/1352458507082600
[42]
Sospedra M, Zhao Y, zur Hausen H, Muraro PA, Hamashin C, et al. (2005) Recognition of conserved amino acid motifs of common viruses and its role in autoimmunity. PLoS Pathog 1: e41. doi: 10.1371/journal.ppat.0010041
[43]
Emmer A, Gerlach K, Staege MS, Kornhuber ME (2008) Cerebral gene expression of superantigen encephalitis in the Lewis rat induced by staphylococcal enterotoxin A. Scand J Immunol. 67: 464–472. doi: 10.1111/j.1365-3083.2008.02094.x
[44]
Ota T, Suzuki Y, Nishikawa T, Otsuki T, Sugiyama T, et al. (2004) Complete sequencing and characterization of 21,243 full-length human cDNAs. Nat Genet 36: 40–45.
[45]
La Mantia G, Maglione D, Pengue G, Di Cristofano A, Simeone A, et al. (1991) Identification and characterization of novel human endogenous retroviral sequences preferentially expressed in undifferentiated embryonal carcinoma cells. Nucleic Acids Res 19: 1513–1520. doi: 10.1093/nar/19.7.1513
[46]
Abrarova ND, Stukacheva EA, Pleshkan VV, Vinogradova TV, Sverdlov ED (2010) Functional analysis of the HERV-K LTR residing in the KIAA1245/NBPF subfamily genes. Mol Biol+ 44: 552–558. doi: 10.1134/s0026893310040084
[47]
Newell GR, Mills PK, Johnson DE (1984) Epidemiologic comparison of cancer of the testis and Hodgkin's disease among young males. Cancer 54: 1117–1123. doi: 10.1002/1097-0142(19840915)54:6<1117::aid-cncr2820540633>3.0.co;2-y
[48]
Kovanen PE, Bernard J, Al-Shami A, Liu C, Bollenbacher-Reilley J, et al. (2008) T-cell development and function are modulated by dual specificity phosphatase DUSP5. J Biol Chem 283: 17362–17369. doi: 10.1074/jbc.m709887200
[49]
Vermeer MH, van Doorn R, Dijkman R, Mao X, Whittaker S, et al. (2008) Novel and highly recurrent chromosomal alterations in Sézary syndrome. Cancer Res 68: 2689–98. doi: 10.1158/0008-5472.can-07-6398
[50]
Ortega-Paino E, Fransson J, Ek S, Borrebaeck CA (2008) Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. Blood 111: 1617–1624. doi: 10.1182/blood-2007-02-068791
[51]
Kucharska A, Rushworth LK, Staples C, Morrice NA, Keyse SM (2009) Regulation of the inducible nuclear dual-specificity phosphatase DUSP5 by ERK MAPK. Cell Signal 21: 1794–1805. doi: 10.1016/j.cellsig.2009.07.015
[52]
Watanabe M, Nakano K, Togano T, Nakashima M, Higashihara M, et al. (2011) Targeted repression of overexpressed CD30 donwregulates NF-kappaB and ERK1/2 pathway in Hodgkin lymphoma cell lines. Oncol Res 19: 463–469. doi: 10.3727/096504012x13285365944292
[53]
Watanabe M, Sasaki M, Itoh K, Higashihara M, Umezawa K, et al. (2005) JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res 65: 7628–76234.
[54]
Zheng B, Fiumara P, Li YV, Georgakis G, Snell V, et al. (2003) MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102: 1019–1027. doi: 10.1182/blood-2002-11-3507
[55]
Hughes R, Gilley J, Kristiansen M, Ham J (2011) The MEK-ERK pathway negatively regulates bim expression through the 3' UTR in sympathetic neurons. BMC Neurosci 12: 69. doi: 10.1186/1471-2202-12-69
[56]
Jeong DG, Cho YH, Yoon TS, Kim JH, Ryu SE, et al. (2007) Crystal structure of the catalytic domain of human DUSP5, a dual specificity MAP kinase protein phosphatase. Proteins 66: 253–258. doi: 10.1002/prot.21224
[57]
Hwang J, Kim YK (2013) When a ribosome encounters a premature termination codon. BMB Rep 46: 9–16. doi: 10.5483/bmbrep.2013.46.1.002
[58]
Xu Z, Poidevin M, Li X, Li Y, Shu L, et al. (2013) Expanded GGGGCC repeat RNA associated with amyotrophic lateral sclerosis and frontotemporal dementia causes neurodegeneration. Proc Natl Acad Sci U S A 110: 7778–8310. doi: 10.1073/pnas.1219643110
[59]
Clybouw C, McHichi B, Mouhamad S, Auffredou MT, Bourgeade MF, et al. (2005) EBV infection of human B lymphocytes leads to down-regulation of Bim expression: relationship to resistance to apoptosis. J Immunol 175: 2968–2973.
[60]
Yip KW, Li A, Li JH, Shi W, Chia MC, et al. (2004) Potential utility of BimS as a novel apoptotic therapeutic molecule. Mol Ther 10: 533–544. doi: 10.1016/j.ymthe.2004.05.026
[61]
Anderton E, Yee J, Smith P, Crook T, White RE, Allday MJ (2008) Two Epstein-Barr virus (EBV) oncoproteins cooperate to repress expression of the proapoptotic tumour-suppressor Bim: clues to the pathogenesis of Burkitt's lymphoma. Oncogene 27: 421–433. doi: 10.1038/sj.onc.1210668
[62]
Paschos K, Smith P, Anderton E, Middeldorp JM, White RE, Allday MJ (2009) Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5: e1000492. doi: 10.1371/journal.ppat.1000492
[63]
Paschos K, Parker GA, Watanatanasup E, White RE, Allday MJ (2012) BIM promoter directly targeted by EBNA3C in polycomb-mediated repression by EBV. Nucleic Acids Res 40: 7233–7246. doi: 10.1093/nar/gks391
